ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
62.64
-0.80 (-1.26%)
Jul 2, 2024, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Revenue
ANI Pharmaceuticals had revenue of $517.46M in the twelve months ending March 31, 2024, with 44.26% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $137.43M with 28.70% year-over-year growth. In the year 2023, ANI Pharmaceuticals had annual revenue of $486.82M with 53.87% growth.
Revenue (ttm)
$517.46M
Revenue Growth
+44.26%
P/S Ratio
2.54
Revenue / Employee
$806,012
Employees
642
Market Cap
1.31B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 486.82M | 170.43M | 53.87% |
Dec 31, 2022 | 316.39M | 100.25M | 46.38% |
Dec 31, 2021 | 216.14M | 7.66M | 3.67% |
Dec 31, 2020 | 208.48M | 1.93M | 0.93% |
Dec 31, 2019 | 206.55M | 4.97M | 2.47% |
Dec 31, 2018 | 201.58M | 24.73M | 13.99% |
Dec 31, 2017 | 176.84M | 48.22M | 37.49% |
Dec 31, 2016 | 128.62M | 52.30M | 68.53% |
Dec 31, 2015 | 76.32M | 20.35M | 36.36% |
Dec 31, 2014 | 55.97M | 25.89M | 86.06% |
Dec 31, 2013 | 30.08M | 27.78M | 1,207.49% |
Dec 31, 2012 | 2.30M | 1.87M | 428.71% |
Dec 31, 2011 | 435.16K | -2.04M | -82.41% |
Dec 31, 2010 | 2.47M | 1.22M | 96.67% |
Dec 31, 2009 | 1.26M | -2.52M | -66.73% |
Dec 31, 2008 | 3.78M | 3.29M | 666.82% |
Dec 31, 2007 | 493.05K | -13.94M | -96.59% |
Dec 31, 2006 | 14.44M | 14.18M | 5,496.12% |
Dec 31, 2005 | 258.00K | 180.00K | 230.77% |
Dec 31, 2004 | 78.00K | 12.51K | 19.09% |
Dec 31, 2003 | 65.49K | -2.70M | -97.64% |
Dec 31, 2002 | 2.77M | 1.02M | 58.53% |
Dec 31, 2001 | 1.75M | 1.52M | 667.35% |
Dec 31, 2000 | 227.72K | 29.04K | 14.61% |
Dec 31, 1999 | 198.68K | - | - |
Dec 31, 1998 | 0 | - | - |
Dec 31, 1997 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.25B |
Brookdale Senior Living | 3.05B |
Tilray Brands | 743.25M |
Pacira BioSciences | 681.75M |
BioCryst Pharmaceuticals | 355.40M |
Kiniksa Pharmaceuticals | 301.77M |
Nurix Therapeutics | 80.89M |
Avadel Pharmaceuticals | 55.14M |
ANIP News
- 18 hours ago - ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP - GlobeNewsWire
- 4 days ago - ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM - Business Wire
- 6 days ago - SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc. - Accesswire
- 7 days ago - ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner - GlobeNewsWire
- 8 days ago - ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences - GlobeNewsWire
- 4 weeks ago - ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) - PRNewsWire
- 6 weeks ago - ANI Pharmaceuticals Announces the Launch of Kionex® Suspension - GlobeNewsWire